Cargando…

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

SIMPLE SUMMARY: Pancreatic cancer is currently difficult to treat, but the drug cisplatin represents one of the most important therapeutic options. We find that cells derived from this cancer fall into two classes regarding their sensitivity towards cisplatin, and we observe that cells with high exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ewers, Katharina M., Patil, Shilpa, Kopp, Waltraut, Thomale, Jürgen, Quilitz, Tabea, Magerhans, Anna, Wang, Xin, Hessmann, Elisabeth, Dobbelstein, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699576/ https://www.ncbi.nlm.nih.gov/pubmed/34944784 http://dx.doi.org/10.3390/cancers13246163

Ejemplares similares

A Purine Analog Synergizes with Chloroquine (CQ) by Targeting Plasmodium falciparum Hsp90 (PfHsp90)
por: Shahinas, Dea, et al.
Publicado: (2013)

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
por: Schulz, Ramona, et al.
Publicado: (2012)

Hsp90 inhibition sensitizes DLBCL cells to cisplatin
por: Schmidt, Linnéa, et al.
Publicado: (2022)

Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions
por: Zagouri, Flora, et al.
Publicado: (2010)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
por: Patil, Shilpa, et al.
Publicado: (2021)

Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development
por: Chen, Chia-Chi, et al.
Publicado: (2018)

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters
por: Henningsen, Kester Mo, et al.
Publicado: (2021)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
por: Schulz, Ramona, et al.
Publicado: (2012)

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
por: Schulz, Ramona, et al.
Publicado: (2012)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
por: Versemann, Lennart, et al.
Publicado: (2022)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
por: Vaseva, A V, et al.
Publicado: (2011)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer
por: Wang, Daojuan, et al.
Publicado: (2023)

Correction: The integrated stress response induces R-loops and hinders replication fork progression
por: Choo, Josephine Ann Mun Yee, et al.
Publicado: (2020)

The integrated stress response induces R-loops and hinders replication fork progression
por: Choo, Josephine Ann Mun Yee, et al.
Publicado: (2020)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Basal and dynamics mRNA expression of muscular HSP108, HSP90, HSF-1 and HSF-2 in thermally manipulated broilers during embryogenesis
por: Al-Zghoul, Mohamed Borhan, et al.
Publicado: (2019)

The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
por: Lackie, Rachel E., et al.
Publicado: (2017)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
por: Fan, Chi-Shuan, et al.
Publicado: (2019)

Hsp40s Specify Functions of Hsp104 and Hsp90 Protein Chaperone Machines
por: Reidy, Michael, et al.
Publicado: (2014)

Control of Canalization and Evolvability by Hsp90
por: Milton, Claire C., et al.
Publicado: (2006)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Hsp90 depletion goes wild
por: Siegal, Mark L, et al.
Publicado: (2012)

The ‘active life’ of Hsp90 complexes()
por: Prodromou, Chrisostomos
Publicado: (2012)

Hsp90, the Concertmaster: Tuning Transcription
por: Khurana, Nidhi, et al.
Publicado: (2015)

Hsp90 Promotes Kinase Evolution
por: Lachowiec, Jennifer, et al.
Publicado: (2015)

Targeting Hsp90 in urothelial carcinoma
por: Chehab, Mahmoud, et al.
Publicado: (2015)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_d194ck5r3ghr9dm16v6slrmcab